Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
10 juin 2022 10h30 HE
|
Agios Pharmaceuticals, Inc.
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at...
Agios Announces Evolution of Research Organization
16 mai 2022 16h15 HE
|
Agios Pharmaceuticals, Inc.
– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July – – Company to Focus Internal Research Efforts on...
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
12 mai 2022 10h00 HE
|
Agios Pharmaceuticals, Inc.
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions – – Agios to...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
10 mai 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Reports Business Highlights and First Quarter 2022 Financial Results
05 mai 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease...
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
21 avr. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
14 avr. 2022 08h34 HE
|
Agios Pharmaceuticals, Inc.
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – –...
Agios to Participate in March Investor Conferences
28 févr. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First...
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
17 févr. 2022 15h41 HE
|
Agios Pharmaceuticals, Inc.
– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status – – Company to Provide Robust Patient Access...